Lilly Falls on Oral Obesity Pill as FDA Decision Looms
Eli Lilly stock fell about 5% as investors awaited the FDA's April decision on orforglipron. Novo Nordisk's intensifi...
Stock index values update on scheduled times or upon data arrivals, varying by index and exchange. This piece covers the timing and implications.
22,965 articlesEli Lilly stock fell about 5% as investors awaited the FDA's April decision on orforglipron. Novo Nordisk's intensifi...
Walmart and Costco sit at opposite ends of the retail revenue spectrum, yet their growth stories diverge in meaningfu...
SpaceX is courting attention ahead of a potential Nasdaq debut. Some ETFs offer pre-IPO exposure via SPVs, but the st...
Credo Technology rides a surge in AI infrastructure demand, but the path to $500 by 2030 hinges on durable revenue gr...
TD Bank has been on investors' radars, but sustained upside hinges on three core drivers. Explore how regulatory shif...
Mosaic’s rare earths could become a new growth engine as the company partners with Rainbow Rare Earths to recover NdP...
Susquehanna lifts Baidu's price target to $140 while maintaining a Neutral rating, citing AI Cloud strength but ongoi...
Teva is turning the corner with a growing biosimilars roster and improving margins. This article examines whether tev...
A crypto treasury firm AVAX faced Nasdaq scrutiny but bounced back after a strategic reverse split. This article brea...
As orthofix prepares its 2025 earnings narrative, investors weigh product mix shifts, margins, and macro headwinds. T...
Two early leaders in the electric air taxi race collide with a policy signal that could tilt the field. This analysis...
SpaceX finally opened its doors to public markets, signaling a pivotal moment for growth investors. This guide breaks...